These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

728 related articles for article (PubMed ID: 30382600)

  • 1. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up.
    Porpiglia F; Fiori C; Amparore D; Kadner G; Manit A; Valerio M; Nicolaas L; Ho BSH; Alonso S; Schulman C; Barber N
    BJU Int; 2019 Jun; 123(6):1061-1069. PubMed ID: 30382600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up.
    Porpiglia F; Fiori C; Bertolo R; Garrou D; Cattaneo G; Amparore D
    BJU Int; 2015 Aug; 116(2):278-87. PubMed ID: 25382816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study.
    Kadner G; Valerio M; Giannakis I; Manit A; Lumen N; Ho BSH; Alonso S; Schulman C; Barber N; Amparore D; Porpiglia F
    World J Urol; 2020 Dec; 38(12):3235-3244. PubMed ID: 32124019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction.
    Porpiglia F; Fiori C; Bertolo R; Giordano A; Checcucci E; Garrou D; Cattaneo G; De Luca S; Amparore D
    BJU Int; 2018 Jul; 122(1):106-112. PubMed ID: 29359881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study.
    De Nunzio C; Cantiello F; Fiori C; Crocerossa F; Tognoni P; Amparore D; Baldassarri V; Elbers JR; Sancha FG; Porpiglia F
    World J Urol; 2021 Jun; 39(6):2037-2042. PubMed ID: 32851439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction.
    Amparore D; Fiori C; Valerio M; Schulman C; Giannakis I; De Cillis S; Kadner G; Porpiglia F
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):349-357. PubMed ID: 33005003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First- and Second-Generation Temporary Implantable Nitinol Devices As Minimally Invasive Treatments for BPH-Related LUTS: Systematic Review of the Literature.
    Amparore D; De Cillis S; Volpi G; Checcucci E; Manfredi M; Morra I; Di Dio M; Fiori C; Porpiglia F;
    Curr Urol Rep; 2019 Jul; 20(8):47. PubMed ID: 31278441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results.
    Amparore D; De Cillis S; Schulman C; Kadner G; Fiori C; Porpiglia F
    Minerva Urol Nephrol; 2023 Dec; 75(6):743-751. PubMed ID: 37350585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial.
    Chughtai B; Elterman D; Shore N; Gittleman M; Motola J; Pike S; Hermann C; Terrens W; Kohan A; Gonzalez RR; Katz A; Schiff J; Goldfischer E; Grunberger I; Tu LM; Alshak MN; Kaminetzky J
    Urology; 2021 Jul; 153():270-276. PubMed ID: 33373708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years.
    Sievert KD; Schonthaler M; Berges R; Toomey P; Drager D; Herlemann A; Miller F; Wetterauer U; Volkmer B; Gratzke C; Amend B
    World J Urol; 2019 Jul; 37(7):1353-1360. PubMed ID: 30283994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-man Safety and Efficacy of the ClearRing Implant for the Treatment of Benign Prostatic Hyperplasia.
    Vjaters E; Nitsan D; Mullerad M; Engelstein D; Leibovitch I; Feld Y
    Eur Urol Focus; 2020 Jan; 6(1):131-136. PubMed ID: 30293945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Technologies for the Surgical Management of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Obstruction. A Systematic Review.
    Dey A; Mamoulakis C; Hasan N; Yuan Y; Shakil A; Omar MI
    Eur Urol Focus; 2024 May; 10(3):400-409. PubMed ID: 37741783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transurethral resection of the prostate in kidney transplant recipients: urological and renal functional outcomes at long-term follow-up.
    Volpe A; Billia M; Quaglia M; Vidali M; Marchioro G; Ceratti G; Sogni F; De Lorenzis E; De Angelis P; Airoldi A; Stratta P; Terrone C
    BJU Int; 2013 Aug; 112(3):386-93. PubMed ID: 23496755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates.
    Wang M; Guo L; Duan F; Yuan K; Zhang G; Li K; Yan J; Wang Y; Kang H
    BJU Int; 2016 Jan; 117(1):155-64. PubMed ID: 25851432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
    Woo HH; Huang CP; Huang WJ; Chang YH; Lien CS; Chkhotua A; Elterman DS
    Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):576-582. PubMed ID: 35641601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Results From a Prospective FDA-Approved Investigational Device Exemption Study.
    Salem R; Hairston J; Hohlastos E; Riaz A; Kallini J; Gabr A; Ali R; Jenkins K; Karp J; Desai K; Thornburg B; Casalino D; Miller F; Hofer M; Hamoui N; Mouli S
    Urology; 2018 Oct; 120():205-210. PubMed ID: 30036614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study.
    Roehrborn CG; Gange SN; Shore ND; Giddens JL; Bolton DM; Cowan BE; Brown BT; McVary KT; Te AE; Gholami SS; Rashid P; Moseley WG; Chin PT; Dowling WT; Freedman SJ; Incze PF; Coffield KS; Borges FD; Rukstalis DB
    J Urol; 2013 Dec; 190(6):2161-7. PubMed ID: 23764081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of preoperative detrusor underactivity on long-term surgical outcomes of photovaporization and holmium laser enucleation in men with benign prostatic hyperplasia: a lesson from 5-year serial follow-up data.
    Cho MC; Yoo S; Park J; Cho SY; Son H; Oh SJ; Paick JS
    BJU Int; 2019 May; 123(5A):E34-E42. PubMed ID: 30582661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aquablation therapy for symptomatic benign prostatic hyperplasia: a single-centre experience in 47 patients.
    Desai MM; Singh A; Abhishek S; Laddha A; Pandya H; Ashrafi AN; Ganpule AP; Roehrborn CG; Thomas AJ; Desai M; Sabnis RB
    BJU Int; 2018 Jun; 121(6):945-951. PubMed ID: 29319914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of novel minimally invasive treatments for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Madersbacher S; Roehrborn CG; Oelke M
    BJU Int; 2020 Sep; 126(3):317-326. PubMed ID: 32599656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.